Black Diamond Therapeutics, Inc. (BDTX) intrinsic value & 10-year financials
Black Diamond Therapeutics, Inc. (BDTX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue reached to $70.0M, with an average return on invested capital of -20.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.72
- Market cap
- $99.0M
- Revenue (FY2025)
- $70.0M
- ROIC (10-yr avg)
- -20.2%
- Free cash flow (FY2025)
- —
BDTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $70.0M | $22.4M | $0.39 | — | 17.9% | 14.6% |
| FY2024 | $0 | -$69.7M | -$1.27 | — | — | -106.2% |
| FY2023 | — | -$82.4M | -$1.88 | -$66.8M | — | -91.3% |
| FY2022 | — | -$91.2M | -$2.52 | -$85.3M | — | -70.1% |
| FY2021 | — | -$125.6M | -$3.47 | -$102.9M | — | -57.8% |
| FY2020 | $0 | -$67.3M | -$2.05 | -$52.3M | — | -24.8% |
| FY2019 | $0 | -$35.3M | — | -$24.7M | — | 93.6% |
| FY2018 | $0 | -$8.9M | — | -$8.5M | — | 80.2% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Black Diamond Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Black Diamond Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -55.9% ROIC.
Black Diamond Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Black Diamond Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.